Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited)

v3.23.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 35 $ 96,608 $ (41,904) $ 54,739
Beginning balance, shares at Dec. 31, 2021   34,917,907      
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 3,537 3,537
Stock-based compensation - PAVmed Inc. 2014 Equity Plan   298 298
Net loss   (12,270) (12,270)
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan   187 187
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares   253,889      
Ending balance, value at Mar. 31, 2022 $ 35 100,630 (54,174) 46,491
Ending balance, shares at Mar. 31, 2022   35,171,796      
Beginning balance, value at Dec. 31, 2022 $ 41 121,081 (98,075) 23,047
Beginning balance, shares at Dec. 31, 2022 40,518,792      
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 2,817 2,817
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 391 391
Vest - restricted stock awards
Vest restricted stock awards, shares   219,320      
APA-RDx - Termination payment 713 713
APA RDx termination payment, shares   553,436      
Issuance - At-The-Market Facility, net of deferred financing charges $ 1 283 284
Issuance - At-The-Market Facility, net of deferred financing charges, shares   230,068      
Purchase - Employee Stock Purchase Plan 276 276
Purchase - Employee Stock Purchase Plan, shares   231,987      
Issuance - Series A Preferred Stock $ 13,625 13,625
Issuance - Series A Preferred Stock, shares 13,625        
Net loss (16,247) (16,247)
Ending balance, value at Mar. 31, 2023 $ 13,625 $ 42 $ 125,561 $ (114,322) $ 24,906
Ending balance, shares at Mar. 31, 2023 13,625 41,753,603